
Zhongzhi Pharmaceutical Holdings Limited
3737.HKHKSEHealthcareDrug Manufacturers - Specialty & Generic
最新資料
HK$0.685
+HK$0.005 · +0.74%
3737.HK公司概覽
盤中時間採用HKT。市場資料可能有所延遲。
公司概況
公司網站Zhongzhi Pharmaceutical Holdings Limited, an investment holding firm based in the People's Republic of China, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing and distribution. Its operations are structured across three main divisions: pharmaceutical production, management of its physical retail pharmacy chain, and its online pharmacy platform. The company offers Chinese patent medicines and traditional Chinese decoction pieces, marketed under prominent brands such as Zeus, Liumian, and Caojinghua. In addition to its core pharmaceutical activities, Zhongzhi also produces and sells food products and traditional Chinese herbs, manages properties, and offers detection and testing services. By the end of 2021, the company managed a network of 398 self-owned retail pharmacies. Of these, 361 were approved for medical insurance payments and are situated in Zhongshan, Guangdong Province, operating under the Zeus brand. Established in 1993, the company's headquarters are also located in Zhongshan, PRC. Crystal Talent Investment Group Limited holds a controlling stake in Zhongzhi Pharmaceutical Holdings Limited.
- 產業
- Drug Manufacturers - Specialty & Generic
- 部門
- Healthcare
- 總部
- CN
- 執行長
- Ying Feng Lai
- 上市以來
- 2015年7月13日
- 僱員
- 2,284
市場位置
- 成交量
- 23.3萬
- 0.6× 平均值
- 平均成交量
- 38.75萬
- 日均成交量
- 市值
- 5.78億 HKD
- 貝塔
- 0.42
- 市場參考 1
財務數據
財務快照
最近十二個月財務健康
- 奧特曼 Z 分數
- 3.71
- 皮奧特羅斯基 F 分數
- 6 共 9 個
財報歷史與展望
- 最新財年每股收益
- 0.021
- 2025會計年度 · 年增-81.36%
- 最新財年收入
- 17.37億 CNY
- 2025會計年度 · 年增-21.55%
年度每股收益趨勢
已公布業績及可用的市場共識預估。
年度營收趨勢
已公布業績及可用的市場共識預估。
3737.HK同業公司
繼續GoAI的研究
在 GoAI 中研究3737.HKresearch.disclaimer





